A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Activity of Ibudilast (MN-166) in Subjects With Progressive Multiple Sclerosis

Trial Profile

A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Activity of Ibudilast (MN-166) in Subjects With Progressive Multiple Sclerosis

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Feb 2018

At a glance

  • Drugs Ibudilast (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms SPRINT-MS
  • Sponsors MediciNova
  • Most Recent Events

    • 18 Feb 2018 According to a MediciNova media release, top-line results will be presented at the the American Academy of Neurology (AAN) 70th Annual Meeting.
    • 01 Feb 2018 Results published in the MediciNova Media Release
    • 31 Jan 2018 According to a MediciNova media release, top-line results will be presented at the third annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top